Poxel S.A.
EPA:POXEL.PA
Overview | Financials
Company Name | Poxel S.A. |
Symbol | POXEL.PA |
Currency | EUR |
Price | 0.53 |
Market Cap | 28,052,455 |
Dividend Yield | 0% |
52-week-range | 0.297 - 0.95 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Thomas Kuhn M.B.A., Pharm D MBA, Pharm.D. |
Website | https://www.poxelpharma.com |
An error occurred while fetching data.
About Poxel S.A.
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is Imeglimin, an oral drug candidate, which completed Phase III clinical development stage in Japan, as well as in Phase III in the United States and Europe for
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD